To the editor: I read with great interest Bonnot et al.'s review of psychopharmacotherapy for Prader-Willi Syndrome (PWS). Given the frequency with which comorbid psychiatric conditions are present in patients with PWS, establishing evidencebased therapies is of critical importance.
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Within the strengths of this article (e.g., clinical relevance), there was limited discussion of behavioral psychotherapeutic interventions for comorbid psychiatric conditions in PWS. This is of particular concern given the limited information that can be concluded based on the strength of the available literature, which consists of case reports and small open trials. The side effect profile of many medications, especially antipsychotics (i.e., weight gain, increased appetite), makes their use a last resort in this population, and some parents may find pharmacotherapy an undesirable treatment approach. Tailored behavioral interventions have demonstrated sound efficacy among youth with developmental disabilities in treating anxiety/ obsessive-compulsive symptoms [1] , disruptive behavior [2] , and self-injury [3] with a negligible side effect profile; preliminary effectiveness among youth with PWS presenting with obsessive-compulsive and skin picking symptoms has been demonstrated [4] . Thus, clinicians should base treatment decisions on a complete assessment of all available therapies; when data are limited in PWS, extrapolation from the treatment literature in disorders with similar phenomenology may be appropriate to most effectively and safely treat the affected individual.
In sum, the reader should use caution in applying findings from this report into their clinical practice given the strength of the current literature supporting pharmacotherapy. Behavioral interventions may be an important treatment component for this population, and the psychiatric care of patients with PWS should be multidisciplinary involving physicians, psychologists, and other allied health professionals. Collectively, the limited available data on pharmacological and behavioral interventions highlight the need for further clinical trials investigating potentially viable therapies that incorporate outcome instruments designed for and validated in people with PWS. 
